cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE 01:00:00 03/11/2026 +04			5-day change	1st Jan Change
0.3967 ^USD	+3.66%		+8.74%	-70.61%

11-02	CbdMD, Inc. completed the acquisition of Operating assets and brands of Twinlab Consolidation Corporation.	CI
09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-14

More transcripts

Analysts' recommendations: cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
02/11/26	$0.3967	+3.66%	298,490
30/10/26	$0.3827	-1.34%	48,344
29/10/26	$0.3879	+4.56%	161,237
28/10/26	$0.3710	+0.27%	41,355
27/10/26	$0.3700	+1.43%	31,311

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.3967

Average target price

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - cbdMD, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - cbdMD, Inc.

Company calendar

Market Cap	4.45M 3.97M 3.64M 3.31M 6.21M 421M 6.33M 43.5M 17.53M 222M 16.68M 16.33M 702M	P/E 2026 *	-1.2x	P/E 2027 *	-2.09x
Enterprise Value	4.45M 3.97M 3.64M 3.31M 6.21M 421M 6.33M 43.5M 17.53M 222M 16.68M 16.33M 702M	EV / Sales 2026 *	0.2x	EV / Sales 2027 *	0.16x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

09-24	Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation	PR
09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-14	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-10	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR

1 day	+3.66%
1 week	+8.74%
Current month	+3.66%
1 month	-13.00%
3 months	-21.74%
6 months	-54.40%
Current year	-70.61%

1 week	0.35	0.42
1 month	0.33	0.46
Current year	0.33	1.34
1 year	0.33	2.56
3 years	0.33	13.84
5 years	0.33	727.2
10 years	0.33	2,606.4

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/04/26	Jeffrey Porter	Free	Director	1,572	0.0150%
14/04/26	William Raines	Free	Director	1,572	0.0150%
14/04/26	Bakari Sellers	Free	Director	1,572	0.0150%

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news: cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+3.66%	+8.74%	-54.64%	-92.69%	4.45M
ELI LILLY AND COMPANY	-0.46%	+10.31%	+63.52%	+143.15%	1,257B
JOHNSON & JOHNSON	-0.97%	+1.60%	+43.25%	+80.09%	651B
ABBVIE INC.	-2.05%	+0.73%	+32.47%	+101.62%	510B
ROCHE HOLDING AG	+0.11%	-0.28%	+53.33%	+67.71%	388B
MERCK & CO., INC.	-0.78%	+5.51%	+72.55%	+44.25%	366B
NOVARTIS AG	+0.95%	+3.20%	+33.57%	+59.47%	303B
ASTRAZENECA PLC	+0.13%	+8.52%	+12.54%	+35.48%	288B
AMGEN INC.	-0.12%	+4.68%	+55.97%	+74.59%	252B
GILEAD SCIENCES, INC.	-0.21%	+7.34%	+42.19%	+109.69%	211B
Average	+0.10%	+5.01%	+35.48%	+62.34%	422.67B
Weighted average by Cap.	-0.32%	+5.30%	+49.35%	+93.83%

	2026 *	2027 *
Net sales	21.92M 19.57M 17.96M 16.34M 30.63M 2.08B 31.24M 215M 86.48M 1.1B 82.28M 80.53M 3.46B	28.6M 25.53M 23.43M 21.31M 39.95M 2.71B 40.75M 280M 113M 1.43B 107M 105M 4.51B
Net income	-3.33M -2.97M -2.73M -2.48M -4.66M -315M -4.75M -32.61M -13.14M -166M -12.51M -12.24M -526M	-4.95M -4.42M -4.05M -3.69M -6.91M -468M -7.05M -48.4M -19.51M -247M -18.56M -18.17M -781M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time